Eli Lilly

Lilly’s first weight loss pill wins US nod, to break access barrier

The approval marks a strategic milestone in the fast‑growing GLP‑1 market, where adoption has been limited by needle aversion, dosing complexity and access barriers.

Eli Lilly to buy Centessa Pharmaceuticals for up to $7.8 billion

Lilly will pay $38 a share for Centessa plus a further $9 if three milestone targets are met, according to a statement Tuesday.

Nvidia to invest $1 billion in AI drug laboratory with Eli Lilly

The investment is the latest example of Nvidia using its newfound financial might to cultivate fresh markets for its products.

Cipla: Emerging markets to lead growth in the near term

Distribution collaboration with Eli Lilly for Mounjaro is a key factor to watch

How Eli Lilly’s weight-loss drug Mounjaro gained early lead against Novo Nordisk’s Wegovy in India

Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.

Eli Lilly's Mounjaro becomes second-most sold drug in September, posts Rs 80 cr revenue: Report

Surge in demand and a shift towards higher dosage led to a 42 percent jump in sales of the weight-loss drug, the report said

Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

The company, which launched its blockbuster weight-loss drug Mounjaro in India this year, currently does not operate its own manufacturing facility in the country

Roche to buy 89bio for up to $3.5 billion in obesity push

Roche is seeking to catch up with Novo Nordisk A/S and Eli Lilly & Co., makers of multibillion-dollar blockbusters Wegovy and Zepbound

Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy

Lilly started selling Mounjaro in India in late March for diabetes and obesity, and it was so far available only in 2.5 mg and 5 mg vials

CDSCO allows Lilly to launch weight-loss drug Mounjaro in pen format

The KwikPen is a multi-dose, single-patient-use prefilled pen designed for once-in-a week administration

Eli Lilly may manufacture weight-loss drug Mounjaro in India in future, says CEO David Ricks

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO

Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says

In February last year, Lilly CEO David Ricks told Reuters that it expects to launch Mounjaro, in India as early as next year.

Lupin acquires Huminsulin from Eli Lilly to enhance diabetes care portfolio

Lupin had been marketing Huminsulin through an existing agreement with Lilly India before proceeding to acquire the brand. Huminsulin is used in the treatment of Type 1 and Type 2 diabetes mellitus.

Divis Lab: GLP-1 opportunity to unfold in the medium term

Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.

World Street | Crude oil slumps; Yen drops amid political turmoil; Olympus Corp plunges after CEO drug scandal; and more

From falling oil prices after Israel's retaliatory strike on Iran to Eli Lilly’s weight-loss drug launch in Hong Kong, here’s a look at recent business developments across the world.

World Street | Barnes & Noble founder passes away; Nvidia creates multimillionaires; HBBE rises after ADOR CEO steps down; Bitcoin drops sharply; and more

From Leonard Riggio’s passing and Xpeng’s new electric car models to Eli Lilly’s Zepbound price cut and the recent crypto sell-off, here’s a look at recent business developments around the world.

Alphabet taps Eli Lilly Executive as new CFO replacing Porat

Ashkenazi has served as CFO and executive vice president at the drug maker, where she worked for more than 23 years, Alphabet said

Biocon’s formulations business to outpace API share soon: CEO

Formulations will focus on peptides, a class of drugs that among other things hels in weight loss, said the MD and CEO

Open to market Eli Lilly’s weight loss drugs in India: Cipla CEO

Currently Cipla has the right to sell, promote and distribute two diabetes drugs of Eli Lilly in India

Eli Lilly lifts 2024 revenue guidance by $2 billion on weight-loss pills demand

For Q1 2024, worldwide Mounjaro revenue was $1.81 billion compared with $568.5 million in Q1 2023

US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel

This is the second regulatory delay for the drug, donanemab, after the company released clinical trial data last year that it says showed the treatment to be safe and effective.

Eli Lilly could launch obesity drug in India next year, CEO says

Eli Lilly's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year.

World Street | Maersk takes a long cut; mortgages regain appeal; McDonalds faces pressure

From shipping containers Suez Canal detour to Carrefour refusing to stock PepsiCo products and from Eli Lilly's weight loss drug bet to falling UK mortgage rates, here's a look at some of the developments from the world of business